Cargando…

Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine

Cancer cachexia is a debilitating condition seen frequently in patients with pancreatic ductal adenocarcinoma (PDAC). The underlying mechanisms driving cancer cachexia are not fully understood but are related, at least in part, to the immune response to the tumor both locally and systemically. We hy...

Descripción completa

Detalles Bibliográficos
Autores principales: Gerber, Michael H., Underwood, Patrick W., Judge, Sarah M., Delitto, Daniel, Delitto, Andrea E., Nosacka, Rachel L., DiVita, Bayli B., Thomas, Ryan M., Permuth, Jennifer B., Hughes, Steven J., Wallet, Shannon M., Judge, Andrew R., Trevino, Jose G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321633/
https://www.ncbi.nlm.nih.gov/pubmed/30513792
http://dx.doi.org/10.3390/ijms19123836
_version_ 1783385488159145984
author Gerber, Michael H.
Underwood, Patrick W.
Judge, Sarah M.
Delitto, Daniel
Delitto, Andrea E.
Nosacka, Rachel L.
DiVita, Bayli B.
Thomas, Ryan M.
Permuth, Jennifer B.
Hughes, Steven J.
Wallet, Shannon M.
Judge, Andrew R.
Trevino, Jose G.
author_facet Gerber, Michael H.
Underwood, Patrick W.
Judge, Sarah M.
Delitto, Daniel
Delitto, Andrea E.
Nosacka, Rachel L.
DiVita, Bayli B.
Thomas, Ryan M.
Permuth, Jennifer B.
Hughes, Steven J.
Wallet, Shannon M.
Judge, Andrew R.
Trevino, Jose G.
author_sort Gerber, Michael H.
collection PubMed
description Cancer cachexia is a debilitating condition seen frequently in patients with pancreatic ductal adenocarcinoma (PDAC). The underlying mechanisms driving cancer cachexia are not fully understood but are related, at least in part, to the immune response to the tumor both locally and systemically. We hypothesize that there are unique differences in cytokine levels in the tumor microenvironment and systemic circulation between PDAC tumors and that these varying profiles affect the degree of cancer cachexia observed. Patient demographics, operative factors, oncologic factors, and perioperative data were collected for the two patients in the patient derived xenograft (PDX) model. Human pancreatic cancer PDX were created by implanting fresh surgical pancreatic cancer tissues directly into immunodeficient mice. At PDX end point, mouse tumor, spleen and muscle tissues were collected and weighed, muscle atrophy related gene expression measured, and tumor and splenic soluble proteins were analyzed. PDX models were created from surgically resected patients who presented with different degrees of cachexia. Tumor free body weight and triceps surae weight differed significantly between the PDX models and control (P < 0.05). Both PDX groups had increased atrophy related gene expression in muscle compared to control (FoxO1, Socs3, STAT3, Acvr2b, Atrogin-1, MuRF1; P < 0.05). Significant differences were noted in splenic soluble protein concentrations in 14 of 15 detected proteins in tumor bearing mice when compared to controls. Eight splenic soluble proteins were significantly different between PDX groups (P < 0.05). Tumor soluble proteins were significantly different between the two PDX groups in 15 of 24 detected proteins (P < 0.05). PDX models preserve the cachectic heterogeneity found in patients and are associated with unique cytokine profiles in both the spleen and tumor between different PDX. These data support the use of PDX as a strategy to study soluble cachexia protein markers and also further efforts to elucidate which cytokines are most related to cachexia in order to provide potential targets for immunotherapy.
format Online
Article
Text
id pubmed-6321633
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-63216332019-01-07 Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine Gerber, Michael H. Underwood, Patrick W. Judge, Sarah M. Delitto, Daniel Delitto, Andrea E. Nosacka, Rachel L. DiVita, Bayli B. Thomas, Ryan M. Permuth, Jennifer B. Hughes, Steven J. Wallet, Shannon M. Judge, Andrew R. Trevino, Jose G. Int J Mol Sci Article Cancer cachexia is a debilitating condition seen frequently in patients with pancreatic ductal adenocarcinoma (PDAC). The underlying mechanisms driving cancer cachexia are not fully understood but are related, at least in part, to the immune response to the tumor both locally and systemically. We hypothesize that there are unique differences in cytokine levels in the tumor microenvironment and systemic circulation between PDAC tumors and that these varying profiles affect the degree of cancer cachexia observed. Patient demographics, operative factors, oncologic factors, and perioperative data were collected for the two patients in the patient derived xenograft (PDX) model. Human pancreatic cancer PDX were created by implanting fresh surgical pancreatic cancer tissues directly into immunodeficient mice. At PDX end point, mouse tumor, spleen and muscle tissues were collected and weighed, muscle atrophy related gene expression measured, and tumor and splenic soluble proteins were analyzed. PDX models were created from surgically resected patients who presented with different degrees of cachexia. Tumor free body weight and triceps surae weight differed significantly between the PDX models and control (P < 0.05). Both PDX groups had increased atrophy related gene expression in muscle compared to control (FoxO1, Socs3, STAT3, Acvr2b, Atrogin-1, MuRF1; P < 0.05). Significant differences were noted in splenic soluble protein concentrations in 14 of 15 detected proteins in tumor bearing mice when compared to controls. Eight splenic soluble proteins were significantly different between PDX groups (P < 0.05). Tumor soluble proteins were significantly different between the two PDX groups in 15 of 24 detected proteins (P < 0.05). PDX models preserve the cachectic heterogeneity found in patients and are associated with unique cytokine profiles in both the spleen and tumor between different PDX. These data support the use of PDX as a strategy to study soluble cachexia protein markers and also further efforts to elucidate which cytokines are most related to cachexia in order to provide potential targets for immunotherapy. MDPI 2018-12-01 /pmc/articles/PMC6321633/ /pubmed/30513792 http://dx.doi.org/10.3390/ijms19123836 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gerber, Michael H.
Underwood, Patrick W.
Judge, Sarah M.
Delitto, Daniel
Delitto, Andrea E.
Nosacka, Rachel L.
DiVita, Bayli B.
Thomas, Ryan M.
Permuth, Jennifer B.
Hughes, Steven J.
Wallet, Shannon M.
Judge, Andrew R.
Trevino, Jose G.
Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
title Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
title_full Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
title_fullStr Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
title_full_unstemmed Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
title_short Local and Systemic Cytokine Profiling for Pancreatic Ductal Adenocarcinoma to Study Cancer Cachexia in an Era of Precision Medicine
title_sort local and systemic cytokine profiling for pancreatic ductal adenocarcinoma to study cancer cachexia in an era of precision medicine
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321633/
https://www.ncbi.nlm.nih.gov/pubmed/30513792
http://dx.doi.org/10.3390/ijms19123836
work_keys_str_mv AT gerbermichaelh localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT underwoodpatrickw localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT judgesarahm localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT delittodaniel localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT delittoandreae localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT nosackarachell localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT divitabaylib localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT thomasryanm localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT permuthjenniferb localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT hughesstevenj localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT walletshannonm localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT judgeandrewr localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine
AT trevinojoseg localandsystemiccytokineprofilingforpancreaticductaladenocarcinomatostudycancercachexiainaneraofprecisionmedicine